- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06307340
다중물질 집단을 위한 STAIR-NT 외상 중재의 적용
During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.
연구 개요
상태
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Florida
-
Tallahassee, Florida, 미국, 32306
- Florida State University
-
-
New York
-
Brooklyn, New York, 미국, 11238
- START Treatment and Recovery Centers
-
New York, New York, 미국, 10016
- NYU Langone Health
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- must be 18 years or older,
- be a patient at the START clinic receiving methadone for treatment of opioid use disorder,
- self-report 10+ days of co-use of cocaine and illicit opioids in the past 30-days,
- meet the criteria for stimulant use disorder (cocaine type; mild, moderate or severe) and a score of 3≥ on the PC-PTSD-5.
Exclusion Criteria:
- cognitive impairment that would interfere with their ability to understand study participation as assessed by the researcher,
- does not speak/understand English at a conversational level,
- plans to leave the START clinic in the next 60 days,
- patients who missed methadone doses (inactive) for 30 days or more, or
- having received clinical care from the interventionist(s) in the past 30 days
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: 평소와 같은 치료(TAU)
|
Treatment as usual. |
|
실험적: 적응형 STAIR-NT 중재
|
Adapted version of evidence-based behavioral PTSD intervention. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
완료된 개입 세션 수
기간: 3개월까지
|
3개월까지
|
|
|
소변 약물 검사에 따른 사용 물질 수
기간: 3개월
|
3개월
|
|
|
독성학 결과의 차트 추상화를 기반으로 사용된 물질의 수
기간: 3개월
|
3개월
|
|
|
Proportion of Eligible Participants
기간: Baseline
|
Proportion of persons eligible to enroll in the study of all possible MMT patients approached. Assessed using count data of individuals failing screen. |
Baseline
|
|
Proportion of Eligible Participants who Enroll
기간: Baseline
|
.Proportion of all eligible persons who enroll. Assessed using count data of individuals consented. |
Baseline
|
|
Clinician-Rated Feasibility of Intervention Measure (FIM) Score
기간: Month 3
|
4-item, clinician-rated assessment of the feasibility of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated feasibility. |
Month 3
|
|
Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score
기간: Month 3
|
4-item, clinician-rated assessment of the acceptability of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated acceptability. |
Month 3
|
|
Number of Days of Co-Use of Cocaine and Illicit Opioids
기간: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire. |
Month 3
|
|
Number of Substances Used based on ASI Self-Report
기간: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire, a self-report assessment to gauge the severity of a person's substance abuse. |
Month 3
|
|
PTSD Checklist for DSM-5 (PCL-5) Score
기간: Month 3
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Each item is rated on a scale from 0-4. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items; higher scores indicate greater severity of PTSD. |
Month 3
|
|
Negative Mood Regulation Scale Score
기간: Month 3
|
30-item assessment of individuals' beliefs and expectations regarding their ability to regulate their negative mood and emotions. Each item is rated on a 5-point Likert scale ranging from 1 (not at all effective) to 5 (extremely effective). The total score ranges from 30-150; higher scores indicate more effective negative mood regulation. |
Month 3
|
|
Inventory of Interpersonal Problems Score
기간: Month 3
|
A 127-item, self-report inventory that asks participants to rate a variety of interpersonal problems that may cause distress. The items are divided into two groups: (1) interpersonal inadequacies or inhibitions (78 items), (2) excesses or compulsions (49 items). Participants rate each item on a scale from 0 to 4 on how much difficulty/distress they feel regarding the item. The total score is calculated by adding the item responses; lower scores indicate less difficulty/distress. |
Month 3
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Amanda Bunting, NYU Langone Health
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 22-01058
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Deidentified quantitative assessment data will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. Data will be stored in a data repository. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 공유 기간
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD 공유 액세스 기준
The investigator who proposed to use the data will be granted access upon reasonable request. The data will be stored in a data repository.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .